SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Cao Han PHD

(Last) (First) (Middle)
C/O BIONANO GENOMICS, INC.
9640 TOWNE CENTRE DR #100

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
08/21/2018
3. Issuer Name and Ticker or Trading Symbol
BioNano Genomics, Inc [ BNGO ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Scientific Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 1,413 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (1) 01/14/2019 Common Stock 46 291.04 D
Stock Option (right to buy) (1) 04/01/2020 Common Stock 46 38.52 D
Stock Option (right to buy) (1) 08/09/2021 Common Stock 2,344 42.8 D
Stock Option (right to buy) (1) 01/28/2025 Common Stock 1,599 64.2 D
Stock Option (right to buy) (2) 01/28/2025 Common Stock 2,557 64.2 D
Stock Option (right to buy) (3) 02/06/2027 Common Stock 51,329 1.28 D
Series B Convertible Preferred Stock (4) (4) Common Stock 254,275 0.00 D
Series C Convertible Preferred Stock (4) (4) Common Stock 52,720 0.00 D
Series D Convertible Preferred Stock (4) (4) Common Stock 4,362,062 0.00 D
Series D-1 Convertible Preferred Stock (4) (4) Common Stock 104,167 0.00 D
Series D Convertible Preferred Stock Warrant (Right to Buy) 04/04/2016 03/04/2026 Series D Convertible Preferred Stock 10,731,083 0.41 D
Explanation of Responses:
1. The shares subject to the option are fully vested and exercisable.
2. 25% of the shares vested on January 29, 2016, and the remaining shares vest in 12 equal quarterly installments thereafter.
3. 25% of the shares vested on February 7, 2017, and the remaining shares vest in 12 equal quarterly installments thereafter.
4. The convertible preferred stock is convertible at any time at the holder's election and automatically converts upon the consummation of a qualified public offering of the registrant. There is no expiration date for any series of preferred stock.
Remarks:
/s/ Han Cao, Ph.D. 08/21/2018
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.